- Trial phase
- Phase 2a (terminated)
- Time to market
- Development terminated; no path to market remains for this indication.
- Why 2/10
- AlloNK has been permanently discontinued as of October 27, 2026, there are no remaining hard, dated catalysts for this drug. The defining binary event (continuation vs. termination) has already occurred, and the stock has already reacted (~33% pre-market decline). With no pipeline and a 94% workforce reduction, the company itself is now pursuing strategic alternatives.
AlloNK has been terminated; there are no further catalysts for this drug. The investment thesis now rests entirely on Artiva's strategic alternatives process, potential merger, asset sale, or liquidation, not on the drug itself. The stock's remaining value will depend on cash reserves (which were being preserved via the 94% workforce reduction) and Artiva's ability to find a buyer or partner for any residual assets.
Price Chart
Executive Summary
AlloNK (AB-101) was Artiva Biotherapeutics' lead and only clinical-stage asset, an allogeneic NK cell therapy designed to combine with rituximab for deep B-cell depletion in autoimmune diseases. Despite encouraging early data, promising institutional backing, FDA Fast Track status, and a planned Phase 3 pivotal trial in refractory RA, the program was terminated on October 27, 2026, after longer-term follow-up showed insufficient durability of clinical response and two patient deaths occurred. Artiva is cutting ~94% of its workforce and exploring strategic alternatives (merger, sale, or liquidation). The stock fell ~33% in pre-market trading on the news.
How It Works
AlloNK is an off-the-shelf, donor-derived natural killer (NK) cell therapy designed to be infused into patients without genetic modification. It works together with monoclonal antibodies like rituximab to deeply deplete B-cells (a type of immune cell) through a process called antibody-dependent cellular cytotoxicity (ADCC). The goal was to reset the immune system in autoimmune diseases like rheumatoid arthritis and Sjögren's disease, similar to the concept behind CAR-T cell therapy but using a donor cell rather than the patient's own cells.
Trial Status
AlloNK was being evaluated in a company-sponsored Phase 2a basket trial for refractory rheumatoid arthritis, Sjögren's disease, systemic sclerosis, and myositis, in combination with rituximab plus low-dose cyclophosphamide/fludarabine conditioning. The company had received FDA Fast Track designation for refractory RA (June 2026) and was planning to initiate a Phase 3 registrational trial in H2 2026, with FDA alignment on a single-trial path. However, on October 27, 2026, Artiva announced the discontinuation of all further development, citing that longer-term follow-up showed durability of clinical response did not meet the company's required threshold, despite initial deep B-cell depletion and early clinical activity. Two patient deaths (Grade 5 adverse events), one leukoencephalopathy assessed as likely fludarabine-related neurotoxicity and one sudden death assessed as unrelated, factored into the decision.
The Two-Sided Case
Upcoming Catalysts
- None, AlloNK development has been discontinued. Artiva is evaluating strategic alternatives including a potential merger, business combination, asset sale, or liquidation.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Artiva Biotherapeutics, Inc. 8-K ARTV ·Originating report